Home > Offer to Sell > Other Chemicals > Others > Raloxifene Hydrochloride Anti Estrogen Supplements 82640-04-8 Raloxifene HCL Anti Cancer Steroid
Raloxifene Hydrochloride Anti Estrogen Supplements 82640-04-8 Raloxifene HCL Anti Cancer Steroid
Inquiry
| Post Date: | Oct 09,2017 |
| Expiry Date: | Oct 09,2018 |
| Detailed Description: |
Payment Method: Western Union, MoneyGram,Bank Transfer,Bitcoi Raloxifene Hydrochloride Anti Estrogen Supplements 82640-04-8 Raloxifene HCL Anti Cancer Steroid Basic Info. Name:Raloxifene hydrochloride Synonyms: Raloxifene hcl;Raloxifene hydrochloride;Ly156758; 6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidin; Keoxifene;Keoxifene hydrochloride;Ly 139481;Akos 92138 CAS: 82640-04-8 MF: C28H28ClNO4S MW: 510.04 Assay:99% Standard:USP32 Chemical Properties: Light-Yellow Solid Usage: amino acid, nutrient. A nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic. Packing:1kg/foil bag or as required Description: Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4SHCl, which corresponds to a molecular weight of 510.05 g/mol. Raloxifene HCl is an off-white to pale-yellow solid that is slightly soluble in water. SERMs mimic estrogen in some tissues and have anti-estrogen activity in others. Other SERMs, such as Pfizer's lasofoxifene and Wyeth's bazedoxifene are in the later development phases. Evista (Raloxifene Hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of Raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (Agonism) and and the blockade of estrogenic pathways in other tissues (Antagonism). Usage: Evista is specifically approved for the treatment and prevention of osteoporosis in postmenopausal women, the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. Evista is supplied as a 60 mg tablet designed for oral administration. The recommended initial dose of the drug is one 60 mg tablet daily, which may be administered any time of day without regard to meals. |
| Company: | Guangzhou Kafen Biotech Co.,Ltd [ China ] |
| Contact: | Laura |
| Tel: | +86-020-31121676 |
| Fax: | +8613332873040 |
| Email: | laura@rawroids.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
